Recent Updates
Recently added Catalysts

Ticagrelor

Phase 2

Coronary Artery Disease | Small molecule | Cardiovascular |Bristol-Myers Squibb Company|Last Updated: Dec 5, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment58
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05093790A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy ParticipantsPHASE2 COMPLETED 58 — — Mar 25, 2022Nov 14, 2022Dec 5, 20231 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Change From Baseline in Thrombus Area
Baseline, Day 1 hour 2, Day 2 hour 24

The change from baseline in thrombus area post-treatment with BMS-986141 versus pretreatment. Baseline is defined as the last non-missing result (including repeated and unscheduled assessments) with a collection date-time less than the datetime of study medication.

Secondary Endpoints
Number of Participants Experiencing Abnormal Vital Signs
Vital signs will be collected at check-in and prior to and after each chamber assessment on Days 1 and 2
Number of Participants Experiencing Abnormal Electrocardiogram (ECG) Values
Electrocardiograms were collected at check-in, and 2 and 24 hours after dosing
Number of Participants Experiencing Clinical Lab Abnormalities
From baseline up to 24 hours post dose
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment Arm 1: Ticagrelor + BMS-986141EXPERIMENTAL -
Treatment Arm 2: Aspirin + BMS-986141EXPERIMENTAL -
Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141EXPERIMENTAL -
Treatment Arm 4: BMS-986141EXPERIMENTAL -
Interventions
NameTypeDescription
TicagrelorDRUGSpecified dose on specified days
BMS-986141DRUGSpecified dose on specified days
AspirinDRUGSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersYes
Study Sites1

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: * Male or female between 18 to 75 years of age, inclusive, and body mass index (weight kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 1...

Countries:United Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Coronary Artery Disease 99 trials
CompanyTickerTrialsLead PhaseDrugs
Novo Nordisk A/S Sponsored ADR Class BNVO5PHASE3Ziltivekimab, Tocilizumab, Dobutamine, NaCl 0.9%
Boston Scientific CorporationBSX9PHASE3Undisclosed
Novartis AG Sponsored ADRNVS4PHASE3Inclisiran
Alnylam Pharmaceuticals, IncALNY1PHASE3Zilebesiran
Viatris, Inc.VTRS1PHASE3Selatogrel
NewAmsterdam Pharma Company N.V.NAMS1PHASE3obicetrapib + ezetimibe daily
GE Healthcare Technologies Inc.GEHC3PHASE1Regadenoson
Abbott LaboratoriesABT12 — Undisclosed
HeartFlow, Inc.HTFL5 — Rosuvastatin
Medtronic PlcMDT3NAUndisclosed
Teleflex IncorporatedTFX2NAUndisclosed
AstraZeneca PLCAZN1 — Tezepelumab
BioCardia, Inc.BCDA1NAUndisclosed
Sanofi SA Sponsored ADRSNY1 — alirocumab /2week, statin ± ezetimibe
Johnson & JohnsonJNJ1NAUndisclosed
Orchestra BioMed Holdings, Inc.OBIO1NAUndisclosed
Rhythm Pharmaceuticals, Inc.RYTM2NAUndisclosed
Azienda Ospedaliera Universitaria Integrata VeronaVRNA2 — Undisclosed
Healthcare Services Group, Inc.HCSG1 — Undisclosed
Collegium Pharmaceutical, Inc.COLL1 — Flozin
Unlock Competitive Intelligence